KontRASt-R: An open-label, multicenter follow-up study conducted among participants who had previously taken part in a study sponsored by Novartis on opnurasib (JDQ443) and continued to benefit from either opnurasib alone or in combination with other therapies used in that study. (ChiCTR) - Oct 16, 2026 - P1/2 | N=50 | Not yet recruiting | Sponsor: Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences); Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sci
New P1/2 trial • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
|